Dignitana startar sin verksamhet i Storbritannien

Transkript

1 Pressmeddelande Dignitana AB (publ) Dignitana startar sin verksamhet i Storbritannien DigniCap TM systemet nyligen lanserat vid specialistmöte i Manchester Detta pressmeddelande är tidigare publicerat på engelska, i händelse av avvikelse är det den engelska versionen som gäller. I ett meddelande daterat till den brittiska pressen meddelar Dignitana att man startat sin verksamhet i Storbritannien och introducerat sitt unika skalpkylningssystem DigniCap TM på viktiga sjukhus och kliniker. De första kliniska resultaten har nyligen presenterats från undersökningar utförda vid Bupa Cromwell Hospital i London. Dignitana är mycket nöjd med detta samarbete med detta ledande privatsjukhus i Storbritannien. Bupa Cromwell Hospital betraktas nationellt och internationellt som ett Centre of Excellence vad gäller cancerbehandling. Den officiella starten för Dignitanas verksamhet i Storbritannien skedde vid en nationell cancerkongress för föreningen för cancersjuksköterskor, UKONS (United Kingdom Oncology Nurses Society), och föreningen för cancerapotekare, BOPA (British Oncology Pharmacists Association), i Manchester den oktober i år. Vid denna cancerkongress organiserade Dignitana ett diskussionsmöte, the first Independent UK Scalp Cooling and Psycho Oncology Focus Group. Detta möte leddes av Dr. Lisa Dougherty, Nurse Consultant of The Royal Marsden Hospital i London. Flera internationella onkologer deltog i mötet tillsammans med onkologisk sjukvårdspersonal från både den allmänna sjukvården och privatsjukvården i Storbritannien. Vid detta diskussionsmöte deltog också Professor Hope Rugo från University of California at San Fransisco. Professor Rugo är Principal Investigator för den kliniska undersökning av DigniCap som just startats i USA. Professor Rugo framhöll att jag känner mig hedrad över att få komma hit till denna kongress och presentera de aktiviteter som pågår med DigniCap I USA. Det är också värdefullt för mig att få ta del av den erfarenhet och den kunskap inom området som finns hos de brittiska onkologerna. Dignitana har haft en närvaro i Storbritannien sedan mars i år. Då anställdes Scott McGovern som försäljningsansvarig i Storbritannien. Scott McGovern har en omfattande kunskap om och erfarenhet från den onkologiska marknaden i Storbritannien, bl. a. som Strategy and Sales Manager for Hospital vid Unomedical. Sedan mars har Dignitana startat fem separata kliniska undersökningar av DigniCap inom både det allmänna sjukvårdssystemet och inom privatsjukvården.

2 Dignitana CEO Martin Waleij ger följande kommentar om situationen i Storbritannien: Detta är ett stort steg framåt för Dignitana. Vi är extremt nöjda med utvecklingen, inte minst med att DigniCap nu finns tillgängligt på ett av de ledande privata cancersjukhusen. Vi förväntar oss att Storbritannien blir en av våra stora marknader under 2011 och kommer inom kort komma med mer information om våra samarbeten i Storbrittanien. Pressmeddelandet från Dignitana i Storbritannien bifogas i sin helhet. För ytterligare information Martin Waleij VD Dignitana AB Telefon: E-post: martin.waleij@dignitana.com

3 Dignitana launches business operations in the UK DigniCap TM system launched in the UK at UKONS/ BOPA 2010 Dignitana are pleased to announce the successful launch of their unique scalp cooling system - the DigniCap TM system in the UK and are extremely pleased to announce the first results of the DigniCap in the UK and cooperation with The BUPA Cromwell Hospital, London. After more than 3 years of developing and launching new generation of the DigniCap and success Worldwide, Dignitana officially launched their UK business operations at UKONS (United Kingdom Oncology Nurses Society) and BOPA (British Oncology Pharmacists Association) in Manchester October 14th 15 th, this year. At UKONS, Dignitana facilitated the first Independent UK Scalp Cooling and Psycho Oncology Focus Group, Chaired by Dr. Lisa Dougherty, Nurse Consultant of The Royal Marsden Hospital, London and was attended by Senior Oncology Clinicians from the National Health Service (NHS), from the Private Healthcare sector and with several international oncologists also in attendance. The meeting was independent of any participation from any healthcare provision companies and the transcript of the meeting will be published in the European Journal of Cancer (and/ or British Journal of Nursing) in To be confirmed. Professor Hope Rugo UCSF, Principal Investigator of the Dignitana US trials comments I was honored to be able to make a presentation here at UKONS of our work with the DigniCap in the US and to be able to share the experience and knowledge of the UK oncologists. We expect to present results from our study to the international oncology community in 2011 in close collaboration with Dignitana Dignitana have been present in the UK market since March 2010 and at this time hired UK Sales Manager, Scott McGovern, who brings with him extensive knowledge of the UK oncology and medical device market. Scott has previously worked as Strategy Manager for Hospira and Sales Manager for Unomedical. Since March 2010, Dignitana have established 5 separate independent multi-site clinical trials of the DigniCap TM system within the NHS and the private sector. A more detailed press release on the work with the NHS will be published before the end of the year. Dignitana CEO Martin Waleij comments This is a great leap forward for Dignitana and we are very content with the results so far in the trial and of course to get the first UK customer on board. We expect the UK to be one of our major markets in 2011 UK Sales Manager Scott McGovern comments These ground-breaking independent trials allow the opportunity to prove the enhanced benefits and features of the DigniCap TM system in a UK setting for the first time and most importantly improve the quality of care provided to patients undergoing Chemotherapy Treatment.

4 The oncology department at the BUPA Cromwell is made up of a highly trained specialist team treating the cancer patient with a multidisciplinary approach to their care. Because psychological considerations are viewed as important as physical, Carole Patrick, Oncology Services Manager, and Valentina Baffour-Gyawu, Chemotherapy Day Unit Manager for chemotherapy investigated the importance of quality of life and body images in patients being treated with sometimes aggressive treatment regimes. The BUPA Cromwell team have explored different options to support their patients and have selected the DigniCap TM system because of the ethos of the company, the product and its comfort and effect. Oncology Services Manager Carole Patrick comments; The findings of the trial to date are very encouraging and has prompted us as health care professionals to explore other ways to further advance and influence results. This approach has been agreed at the first scalp cooling group meeting held at UKONS this year driven by BUPA Cromwell and the NHS. For further information Martin Waleij CEO Dignitana AB martin.waleij@dignitana.com

5 Press release Dignitana AB (publ) Dignitana: Dignitana launches business operations in the UK (AktieTorget: DIGN) DigniCapTM - system launched in the UK at UKONS/ BOPA 2010 Dignitana are pleased to announce the successful launch of their unique scalp cooling system - the DigniCapTM -system in the UK and are extremely pleased to announce the first results of the DigniCap in the UK and cooperation with The BUPA Cromwell Hospital, London. After more than 3 years of developing and launching new generation of the DigniCap and success Worldwide, Dignitana officially launched their UK business operations at UKONS (United Kingdom Oncology Nurses Society) and BOPA (British Oncology Pharmacists Association) in Manchester October 14th - 15th, this year. At UKONS, Dignitana facilitated the first Independent UK Scalp Cooling and Psycho Oncology Focus Group, Chaired by Dr. Lisa Dougherty, Nurse Consultant of The Royal Marsden Hospital, London and was attended by Senior Oncology Clinicians from the National Health Service (NHS), from the Private Healthcare sector and with several international oncologists also in attendance. The meeting was independent of any participation from any healthcare provision companies and the transcript of the meeting will be published in the European Journal of Cancer (and/ or British Journal of Nursing) in To be confirmed. Professor Hope Rugo UCSF, Principal Investigator of the Dignitana US trials comments "I was honored to be able to make a presentation here at UKONS of our work with the DigniCap in the US and to be able to share the experience and knowledge of the UK oncologists. We expect to present results from our study to the international oncology community in 2011 in close collaboration with Dignitana" Dignitana have been present in the UK market since March 2010 and at this time hired UK Sales Manager, Scott McGovern, who brings with him extensive knowledge of the UK oncology and medical device market. Scott has previously worked as Strategy Manager for Hospira and Sales Manager for Unomedical. Since March 2010, Dignitana have established 5 separate independent multi-site clinical trials of the DigniCapTM -system within the NHS and the private sector. A more detailed press release on the work with the NHS will be published before the end of the year.

6 Dignitana CEO Martin Waleij comments "This is a great leap forward for Dignitana and we are very content with the results so far in the trial and of course to get the first UK customer on board. We expect the UK to be one of our major markets in 2011" UK Sales Manager Scott McGovern comments "These ground-breaking independent trials allow the opportunity to prove the enhanced benefits and features of the DigniCapTM -system in a UK setting for the first time and most importantly improve the quality of care provided to patients undergoing Chemotherapy Treatment. The oncology department at the BUPA Cromwell is made up of a highly trained specialist team treating the cancer patient with a multidisciplinary approach to their care. Because psychological considerations are viewed as important as physical, Carole Patrick, Oncology Services Manager, and Valentina Baffour-Gyawu, Chemotherapy Day Unit Manager for chemotherapy investigated the importance of quality of life and body images in patients being treated with sometimes aggressive treatment regimes. The BUPA Cromwell team have explored different options to support their patients and have selected the DigniCapTM -system because of the ethos of the company, the product and its comfort and effect. Oncology Services Manager Carole Patrick comments; " The findings of the trial to date are very encouraging and has prompted us as health care professionals to explore other ways to further advance and influence results. This approach has been agreed at the first scalp cooling group meeting held at UKONS this year driven by BUPA Cromwell and the NHS. For further information Martin Waleij CEO Dignitana AB martin.waleij@dignitana.com